Sintez in Kurgan produces more than 95 million packs and vials of medicines
In the first half of 2026, the Sintez pharmaceutical plant in Kurgan, part of Binnopharm Group, produced more than 95.4 million packs and vials of medicines. Antibiotics, one of the plant’s key product categories, accounted for more than 72% of total production volume.
During the first six months of 2026, the plant increased production of several antibiotics. Ampicillin output rose by 38% year-on-year to 9.4 million vials, while levofloxacin production increased by 55% to 1.5 million vials. Sultasin production grew by 12% to 285,000 vials, Sulfotaxime output increased 3.4-fold to 111,000 vials, and linezolid production rose by 35% to 36,000 packs. Cefepime production also doubled, reaching 851,000 vials.
«Sintez supplies medicines to patients across Russia and beyond. In the first half of the year alone, the plant produced more than 39 million packs and vials of medicines for delivery to Azerbaijan, Armenia, Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, and Uzbekistan. Maintaining high product quality and reliable supplies is particularly important to us, as many of our medicines are socially significant», said Andrey Khairullin, Sintez's executive director.
The medicines produced during the first half of the year included antibiotics, antiviral and antimicrobial medicines, antidiabetic and antipyretic drugs, anesthetics, eye drops and vasoconstrictor drops, as well as medicines for the treatment of gastrointestinal and cardiovascular diseases.
The Sintez plant in Kurgan is designated as a systemically important enterprise. It produces around 250 million packs and vials of medicines annually. Of its total output, 18% is manufactured using a full-cycle production process, from active pharmaceutical ingredients to finished dosage forms.
